Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies
Based on the success of tumor-infiltrating lymphocytes (TIL)-based therapies, personalized adoptive cell therapies (ACT) targeting neoantigens have the potential to become a disruptive technology and lead to highly effective treatments for cancer patients for whom no other options exist. ACT of TIL,...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-01-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2020.1869389 |
id |
doaj-e35d59547b204fe29fac1882703dfb2d |
---|---|
record_format |
Article |
spelling |
doaj-e35d59547b204fe29fac1882703dfb2d2021-01-15T12:27:49ZengTaylor & Francis GroupOncoImmunology2162-402X2021-01-0110110.1080/2162402X.2020.18693891869389Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapiesFlorian Kast0Christian Klein1Pablo Umaña2Alena Gros3Stephan Gasser4Roche Innovation Center ZurichRoche Innovation Center ZurichRoche Innovation Center ZurichCellex CenterRoche Innovation Center ZurichBased on the success of tumor-infiltrating lymphocytes (TIL)-based therapies, personalized adoptive cell therapies (ACT) targeting neoantigens have the potential to become a disruptive technology and lead to highly effective treatments for cancer patients for whom no other options exist. ACT of TIL, peripheral blood or gene-engineered peripheral blood lymphocytes (PBLs) targeting neoantigens is a highly personalized intervention that requires three discrete steps: i) Identification of suitable personal targets (neoantigens), ii) selection of T cells or their T cell receptors (TCRs) that are specific for the identified neoantigens and iii) expansion of the selected T cell population or generation of sufficient number of TCR modified T cells. In this review, we provide an introduction into challenges and approaches to identify neoantigens and to select the Adoptive Cell Therapy, ACT, Neoantigen, T cell, Cancer respective neoantigen-reactive T cells for use in ACT.http://dx.doi.org/10.1080/2162402X.2020.1869389adoptive cell therapyactneoantigent cellcancer |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Florian Kast Christian Klein Pablo Umaña Alena Gros Stephan Gasser |
spellingShingle |
Florian Kast Christian Klein Pablo Umaña Alena Gros Stephan Gasser Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies OncoImmunology adoptive cell therapy act neoantigen t cell cancer |
author_facet |
Florian Kast Christian Klein Pablo Umaña Alena Gros Stephan Gasser |
author_sort |
Florian Kast |
title |
Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies |
title_short |
Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies |
title_full |
Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies |
title_fullStr |
Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies |
title_full_unstemmed |
Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies |
title_sort |
advances in identification and selection of personalized neoantigen/t-cell pairs for autologous adoptive t cell therapies |
publisher |
Taylor & Francis Group |
series |
OncoImmunology |
issn |
2162-402X |
publishDate |
2021-01-01 |
description |
Based on the success of tumor-infiltrating lymphocytes (TIL)-based therapies, personalized adoptive cell therapies (ACT) targeting neoantigens have the potential to become a disruptive technology and lead to highly effective treatments for cancer patients for whom no other options exist. ACT of TIL, peripheral blood or gene-engineered peripheral blood lymphocytes (PBLs) targeting neoantigens is a highly personalized intervention that requires three discrete steps: i) Identification of suitable personal targets (neoantigens), ii) selection of T cells or their T cell receptors (TCRs) that are specific for the identified neoantigens and iii) expansion of the selected T cell population or generation of sufficient number of TCR modified T cells. In this review, we provide an introduction into challenges and approaches to identify neoantigens and to select the Adoptive Cell Therapy, ACT, Neoantigen, T cell, Cancer respective neoantigen-reactive T cells for use in ACT. |
topic |
adoptive cell therapy act neoantigen t cell cancer |
url |
http://dx.doi.org/10.1080/2162402X.2020.1869389 |
work_keys_str_mv |
AT floriankast advancesinidentificationandselectionofpersonalizedneoantigentcellpairsforautologousadoptivetcelltherapies AT christianklein advancesinidentificationandselectionofpersonalizedneoantigentcellpairsforautologousadoptivetcelltherapies AT pabloumana advancesinidentificationandselectionofpersonalizedneoantigentcellpairsforautologousadoptivetcelltherapies AT alenagros advancesinidentificationandselectionofpersonalizedneoantigentcellpairsforautologousadoptivetcelltherapies AT stephangasser advancesinidentificationandselectionofpersonalizedneoantigentcellpairsforautologousadoptivetcelltherapies |
_version_ |
1724337118152491008 |